Skip to main content
Caplight Logo









Immunomic Therapeutics

Immunomic Therapeutics

Private
Rockville, MarylandHealthcare & Life Scienceshttps://immunomix.com/

Last Round

VC Round

Jan 14, 2021

Total Funding Raised

$15.53M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Immunomic Therapeutics is a biotechnology company that develops nucleic acid-based vaccines and immunotherapies for oncology, infectious diseases, and allergies using its proprietary UNITE platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

nucleic acid vaccineimmunotherapybiotechnologylysosomal targetingDNA vaccineoncologyantigen presentationclinical-stage biotechdrug discoverymRNA vaccineT-cell activationbiotech licensingvaccine platformcold tumor therapynext-gen vaccines

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Immunomic Therapeutics Comparables

Compare Immunomic Therapeutics with similar companies based on industry and business-model similarity.

Immunomic Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MimiVax Inc.
81%
Takis S.r.l.
78%
Elicio Therapeutics
77%

Immunomic Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJan 14, 2021
DebtMar 15, 2017
Series AOct 28, 2014
DebtJul 17, 2013
AngelMar 5, 2012

Key People

Founding team and executive leadership

Dong-Gun Kim

Chief Executive Officer

Executive Team

Immunomic Therapeutics Investors

Notable investors and investment history

Immunomic Therapeutics investors
InvestorRounds
Life Sciences Greenhouse InvestmentsDebt
Keiretsu ForumDebt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 6, 3x the trailing average.

  • Jan 14, 2021

    $78M round led by HLB Co., Ltd.

Immunomic Therapeutics Filings

Explore SEC and related filing metadata, where available.

Immunomic Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Immunomic Therapeutics's valuation, stock price, and market status.

Is Immunomic Therapeutics a public or private company?

Immunomic Therapeutics is a private company.

What is the current stock price of Immunomic Therapeutics?

Immunomic Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Immunomic Therapeutics worth (valuation)?

Valuation information for Immunomic Therapeutics is not publicly available.

Can I buy Immunomic Therapeutics stock?

Immunomic Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Immunomic Therapeutics's last funding round?

Immunomic Therapeutics's most recent funding round was VC Round on January 14, 2021.

Who are the main investors in Immunomic Therapeutics?

Key investors in Immunomic Therapeutics include Life Sciences Greenhouse Investments.

Will Immunomic Therapeutics IPO soon?

No public IPO plans have been announced for Immunomic Therapeutics.

How can I track Immunomic Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Immunomic Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersRockville, Maryland
Employee Range16
Year Founded2006
Last FundingJan 14, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?